SOMNOMED LIMITED (SOM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SOM

SOM - SOMNOMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -2.64
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.66

18 Jun
2025

0.040

OPEN

$0.63

6.45%

HIGH

$0.66

23,764

LOW

$0.63

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
SOM: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 10.1 N/A xxx
DPS (cps) xxx 0.0 N/A xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-10.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx91.7 M
Book Value Per Share xxxxxxxxxxxxxxx20.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-6.3 M
Net Profit Margin xxxxxxxxxxxxxxx-13.36 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-36.31 %
Return on Invested Capital xxxxxxxxxxxxxxx-26.47 %
Return on Assets xxxxxxxxxxxxxxx-18.51 %
Return on Equity xxxxxxxxxxxxxxx-36.31 %
Return on Total Capital xxxxxxxxxxxxxxx-17.03 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx7 M
Goodwill - Gross xxxxxxxxxxxxxxx6 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx16 M
Price To Book Value xxxxxxxxxxxxxxx1.21

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx5.3 M
Capex % of Sales xxxxxxxxxxxxxxx5.83 %
Cost of Goods Sold xxxxxxxxxxxxxxx42 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx58 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

06/06/2025

-1

No Rating

-

SomnoMed specialises in the development and manufacture of oral appliance therapy (OAT) devices for treating obstructive sleep apnoea (OSA). Founded in 2004, the company has grown to become the leading global OEM in the dental sleep medicine sector.

In Morgans 'Keeping Stock' coverage, (no rating or target), the broker highlights a swing to profitability over the last 18 months through improved sales and manufacturing capacity increases. Management also implemented a cost-base restructure and repaid debt facilities.

The analysts point to a 19% year-on-year rise in first-half revenue to $53.7m, supported by improved throughput, restructuring benefits, and regional sales growth.

Earnings (EBITDA) turned around to $5.8m, while free cash flow recovered to $1.3m from a -$8.0m outflow, and cash increased to $18.5m from $16.2m, notes the broker.

Manufacturing capacity has expanded over 40%, with turnaround time reduced to under 10 days, positioning the company well for further growth, in Morgans' view.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

29/01/2025

1

Overweight

$0.80

21.21%

Wilson raises its target for SomnoMed by 70% (not a typo) to 80c, maintaining its Overweight rating, citing a strong earnings (EBITDA) recovery and improved operational efficiency following last year’s restructuring.

A 2Q trading update shows group revenue rising by 19% year-on-year to $53.7m, supported by a 37% increase in US sales and better manufacturing capacity, which helped recapture lost customers and reduce turnaround times, explains the broker.

Revenue guidance remains at $105m, while EBITDA guidance has been raised to $7-9m from more than $7m.

The broker notes ongoing demand growth in the global sleep apnoea market, bolstered by increased awareness and referrals, and sees the business benefiting from favourable sector tailwinds.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.30 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.70 cents.
Access Extra Coverage Research History >

SOM STOCK CHART

FNArena News on SOM

1
In Brief: Top Picks In Financials, Retail & Healthcare

Mar 07 2025 - Weekly Reports
2
Australian Broker Call *Extra* Edition – Jan 29, 2025

Jan 29 2025 - Daily Market Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 06-12-24

Dec 06 2024 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Dec 04, 2024

Dec 04 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Oct 31, 2024

Oct 31 2024 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Cochlear Downgrades Ahead Of New Launches

10:30 AM - Australia
2
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
3
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
4
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
5
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
6
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
7
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia
8
The Trend Remains Pro Medicus’ Friend

Jan 16 2025 - Technicals
9
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
10
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia